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Fig. 1. (A) Multiple various sized erythematous to violaceous subcutaneous nodules on both extensor surfaces of elbows. (B) Biopsy 
showed dense fibrinoid deposits in deep dermis (H&E, ×100). (C) Biopsy showed palisading granulomas surrounding degenerated 
connective tissue and fibrin (H&E, ×200).
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Dear Editor:
A 40-year-old male presented with 4 months history of 
multiple various sized erythematous to violaceous sub-
cutaneous nodules on both extensor surfaces of elbows, 
which was partially movable and showed no symptoms 
(Fig. 1A). He was diagnosed as rheumatoid arthritis (RA) 7 
years ago. A variety of therapeutic options, such as sys-
temic corticosteroid, antimalarial drug, nonsteroidal an-
ti-inflammatory drugs (NSAIDs), and methotrexate, were 
prescribed to control RA activity. However, they all failed 
to show symptomatic improvement. After that, the patient 
started adalimumab, a human monoclonal antibody to tu-
mor necrosis factor (TNF)-α, 40 mg injection every other 
week with concomitant systemic corticosteroid, metho-
trexate and a NSAID. Adalimumab injection improved 
signs and symptoms of RA gradually. However, the multi-
ple subcutaneous nodules occurred in the extensor sides 
of the elbows two months after adalimumab injection. A 
skin biopsy was performed and it showed dense fibrinoid 
deposits in deep dermis. At high magnification, large pal-
isading granulomas surrounding degenerated connective 
tissue and fibrin were noticed and infiltrating in-
flammatory cells were mostly composed of lymphocytes 
and histiocytes. Mucin deposition was rarely observed. 
Overall, it was consistent with rheumatoid nodule (Fig. 
1B, C). The patient didn’t receive any treatment, and there 
was no change in the lesion at the follow-up visit. 
Rheumatoid nodule development is extremely rare side ef-
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fect of TNF-α antagonists and only two cases after eta-
nercept and adalimumab injection have reported so far. 
However, in the previous report caused by adalimumab 
injection, rheumatoid nodule was diagnosed by only ultra-
sonogram1. Thus, to our knowledge, this is the first report 
of rheumatoid nodules confirmed by histopathologic diag-
nosis following the treatment with adalimumab.
Rheumatoid nodules are one of the most common ex-
tra-articular manifestations of RA, usually associated with 
severe disease activity. Macrophage is the main infiltrating 
inflammatory cell in both rheumatoid nodule and synovial 
membrane of RA and they show similar expressions of 
proinflammatory cytokines such as TNF-α, and inter-
leukin-1 receptor antagonist (IL-1Ra)2. However, in this 
case, rheumatoid nodules were developed when the signs 
and symptoms of RA had been gradually improving by the 
adalimumab.
There are several differences between rheumatoid nodule 
and synovial membrane of RA. Rheumatoid nodules lack 
infiltrating B cells, plasma cells, and organized lymphoid 
structures. In addition, E-selectin expression, IL-1 level are 
higher and TNF-α concentration is significantly lower in 
the rheumatoid nodule compared to the synovial mem-
brane of RA3, which suggests that development of rheu-
matoid nodules might be less influenced by TNF-α. One 
study with TNF-α knockout mice demonstrated abnor-
mally low TNF-α level might induce an exaggeration of 
the effects driven by other inflammatory mediators4. 
Therefore, it could be considered that excessive TNF-α 
suppression could induce the development of rheumatoid 
nodules.
Furthermore, anti-TNF-α treatments increase peripheral 
blood counts which are thought to be related to reduced 
cell traffic to the inflamed joint in RA5. Thus it is con-
ceivable that these migratory cells infiltrate other inflamed 
tissues and form rheumatoid nodules.
So herein, we report a case with great interest which 
could be one of the example and supporting clinical evi-
dence of the paradoxical effects of anti-TNF-α treatment.
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